Gujarat Themis Biosyn Limited Announces Postal Ballot for Special Resolutions

2 min read     Updated on 06 May 2026, 12:26 PM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Gujarat Themis Biosyn Limited has announced a postal ballot via e-voting for two special resolutions regarding borrowing limits and loan provisions. The e-voting runs from 6th May to 4th June 2026, with results due by 8th June 2026.

powered bylight_fuzz_icon
39596193

*this image is generated using AI for illustrative purposes only.

Gujarat Themis Biosyn Limited has issued a notice to its members regarding a postal ballot to seek approval for special resolutions concerning the company's financial operations. The notice, dated 5th May 2026, outlines the company's intention to secure shareholder consent through remote electronic voting only, adhering to the provisions of the Companies Act, 2013, and relevant SEBI regulations.

Special Resolutions

The company is seeking member approval for two key special resolutions. The first resolution aims to approve an increase in the borrowing limits of the company under Section 180(1)(c) and the creation of a mortgage or charge on the company's assets, properties, or undertakings under Section 180(1)(a) of the Companies Act, 2013. The second resolution seeks approval for limits to give loans, guarantees, or investments, or provide security in connection with loans made to any person or body corporate. It also covers acquiring securities of any other body corporate in excess of the limits prescribed in Section 186 of the Companies Act, 2013.

E-Voting Schedule and Process

Central Depository Services (India) Limited (CDSL) has been engaged to provide the e-voting facility. The remote e-voting period is set to commence on Wednesday, 6th May 2026, at 9:00 a.m. IST and will conclude on Thursday, 4th June 2026, at 5:00 p.m. IST. Voting rights will be reckoned based on the paid-up value of equity shares registered as of the cut-off date, Friday, 1st May 2026.

Key Event Date and Time
Cut-off Date Friday, 1st May 2026
E-Voting Start Wednesday, 6th May 2026, 9:00 a.m. IST
E-Voting End Thursday, 4th June 2026, 5:00 p.m. IST
Result Announcement Latest by Monday, 8th June 2026

Scrutiny and Results

The Board of Directors has appointed Mr. Ketan R. Shirwadkar, Proprietor of M/s. KRS AND CO., as the Scrutinizer to oversee the e-voting process. Following the scrutiny, the Chairman or an authorized person will announce the results within two working days, i.e., by Monday, 8th June 2026. The results, along with the Scrutinizer's Report, will be published on the company's website and the CDSL portal, and subsequently forwarded to the BSE and NSE stock exchanges.

Communication and Grievances

In compliance with Ministry of Corporate Affairs (MCA) circulars, no physical copies of the notice will be dispatched. The Postal Ballot Notice was emailed to members on 5th May 2026. Members who have not registered their email addresses can do so temporarily through the Registrar and Transfer Agent's link. The notice and explanatory statements are also available on the company's website and the websites of BSE, NSE, and CDSL. Any grievances related to e-voting may be addressed to Mr. Rakesh Dalvi, Sr. Manager at CDSL.

Historical Stock Returns for Gujarat Themis Biosyn

1 Day5 Days1 Month6 Months1 Year5 Years
-0.16%+9.60%+51.44%-11.48%+44.62%+63.68%

How might the proposed increase in borrowing limits impact Gujarat Themis Biosyn's debt-to-equity ratio and overall financial leverage in the near term?

What specific expansion projects or capital expenditure plans could Gujarat Themis Biosyn be targeting that necessitate higher borrowing and investment limits under Sections 180 and 186?

How are minority shareholders likely to respond to these resolutions, and could institutional investor opposition potentially block the special resolutions requiring 75% approval?

like15
dislike

Gujarat Themis Biosyn Acquires Sanofi's Anti-TB Portfolio for €158 Million

2 min read     Updated on 25 Apr 2026, 11:14 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Gujarat Themis Biosyn Limited has entered into an Asset Purchase Agreement with Sanofi to acquire 13 established branded generic products in the anti-tuberculosis and anti-infective segment for €158 million in cash. The portfolio has presence across 55+ countries in Europe, Middle East and Africa, with revenues of €66 million (FY23), €67 million (FY24), and €62 million (FY25). The asset-light transaction, which excludes manufacturing facilities and employees, is subject to antitrust and FDI approvals and is expected to close by December 2026, providing immediate access to regulated markets and enabling forward integration from intermediates to finished dosage formulations.

powered bylight_fuzz_icon
38519246

*this image is generated using AI for illustrative purposes only.

Gujarat Themis Biosyn Limited has signed an Asset Purchase Agreement with Sanofi, French holding Company of the Sanofi group headquartered in Paris, for acquiring a portfolio of anti-tuberculosis (TB) and anti-infective brands along with associated trademark rights. The disclosure was made to BSE Limited and National Stock Exchange of India Limited on April 23, 2026, under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Acquisition Overview

The transaction involves the acquisition of 13 established branded generic products with a strong presence across more than 55 countries in Europe, the Middle East and Africa. The portfolio focuses on tuberculosis and anti-infectives segment with key molecules including Rifampicin, Rifapentine, and Levofloxacin. The consideration for the transaction is Euro 158 million payable in cash at closing.

Metric: Details
Number of Brands: 13 established global brands
Geographic Reach: 55+ countries
Deal Value: €158 million
Consideration Type: Cash at closing
Retail Channel Contribution: ~70%

Financial Performance

The concerned portfolio reported net sales of approximately Euro 62 million for the year ended 2025. Revenues from the 13 established branded generic products in the last 3 years were FY23 - Euro 66 million, FY24 - Euro 67 million, and FY25 - Euro 62 million.

Fiscal Year Revenue
FY23 €66 million
FY24 €67 million
FY25 €62 million

Strategic Value and Integration

This Asset Purchase represents a significant step in GTBL's strategy to strengthen its global generic pharmaceuticals platform and expand its presence in the anti-infective segment. The transaction would provide immediate access to regulated and semi-regulated markets, enabling GTBL to enhance its international footprint. It would also create a strong opportunity for forward integration, allowing the company to leverage its existing capabilities in fermentation-based intermediates and APIs to support the acquired finished dosage formulations portfolio and drive improved realizations across the value chain.

Transaction Structure and Timeline

The acquisition includes marketing authorizations, brands, regulatory dossiers and inventory and associated commercial rights. The transaction does not involve the acquisition of any legal entity, manufacturing facilities or employees, making it a capital-efficient and asset-light expansion. The transaction is subject to obtaining antitrust and foreign direct investment approvals in applicable jurisdictions and is expected to be closed by the end of December 2026.

Parameter: Details
Filing Date: April 23, 2026
Regulation: SEBI Regulation 30
Filed By: Vineet Gawankar, Company Secretary
Expected Closing: End of December 2026
Approvals Required: Antitrust and FDI approvals

Historical Stock Returns for Gujarat Themis Biosyn

1 Day5 Days1 Month6 Months1 Year5 Years
-0.16%+9.60%+51.44%-11.48%+44.62%+63.68%

How will Gujarat Themis Biosyn finance the €158 million acquisition and what impact might this have on its debt-to-equity ratio?

What potential regulatory hurdles could delay the December 2026 closure timeline, particularly given the multi-country scope of the portfolio?

How might this acquisition position Gujarat Themis Biosyn against competitors in the global anti-infective market over the next 3-5 years?

like19
dislike

More News on Gujarat Themis Biosyn

1 Year Returns:+44.62%